The predictive value of maternal serum screening tests for adverse pregnancy outcomes

2020 ◽  
Vol 27 (4) ◽  
pp. 1268
Author(s):  
Gulten Ozgen ◽  
Gultekin Aydin
Keyword(s):  
Pregnancy Outcomes ◽  
Predictive Value ◽  
Maternal Serum ◽  
Adverse Pregnancy Outcomes ◽  
Screening Tests ◽  
Maternal Serum Screening ◽  
Serum Screening ◽  
Adverse Pregnancy

scholarly journals Clinical significance of unexplained elevated maternal serum alpha feto-protein in second trimester of pregnancy

2018 ◽  
Vol 7 (6) ◽  
pp. 2245
Author(s):  
Urmila Karya ◽  
Sweta Kumari ◽  
Anupam Rani ◽  
Shakun Singh
Keyword(s):  
Pregnant Women ◽  
Pregnancy Outcome ◽  
Pregnancy Outcomes ◽  
Predictive Value ◽  
Maternal Serum ◽  
Adverse Pregnancy Outcomes ◽  
Alpha Fetoprotein ◽  
Second Trimester ◽  
Serum Alpha Fetoprotein ◽  
Adverse Pregnancy

Background: Alpha-fetoprotein (AFP) is the major serum protein in the embryonic stage and in the early fetal stage. The aim of this study was to measure maternal serum AFP levels in second trimester between 15-20 weeks of gestation and to determine whether unexplained elevated MSAFP levels is an effective predictor of adverse pregnancy outcome among Indian population.Methods: This study was a prospective observational study, carried out on 400 pregnant women. Maternal serum alpha-fetoprotein (MSAFP) was measured between 15 and 20 weeks of gestation after excluding congenital malformation or birth defects. MSAFP level was determined by using a radio-immunoassay technique. Women with MSAFP level >2.0 MoM was considered as abnormal while MSAFP level≤ 2.0 MoM was considered as normal. All women were followed up till delivery and pregnancy outcomes were noted and compared between two groups.Results: Women with elevated MSAFP had significantly higher adverse pregnancy outcomes (75.4%) compared to women with MSAFP ≤2.0 MoM (26.1%) (p<0.0001 with relative risk of 2.89, 95% confidence interval 2.276 -3.667).Conclusions: Unexplained elevated MSAFP has high sensitivity, specificity, positive predictive value and negative predictive value in predicting adverse pregnancy outcomes. It would, therefore be worthwhile screening pregnant women in second trimester for maternal serum alpha-fetoprotein levels as it would help to identify high risk pregnancies and allow close antenatal survillence for better pregnancy outcome.

Association between isolated abnormal levels of maternal serum unconjugated estriol in the second trimester and adverse pregnancy outcomes

2015 ◽  
Vol 29 (13) ◽  
pp. 2093-2097 ◽  
Author(s):  
Thaniyaporn Settiyanan ◽  
Chanane Wanapirak ◽  
Supatra Sirichotiyakul ◽  
Fuanglada Tongprasert ◽  
Kasemsri Srisupundit ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Maternal Serum ◽  
Adverse Pregnancy Outcomes ◽  
Second Trimester ◽  
Adverse Pregnancy ◽  
Unconjugated Estriol

scholarly journals Maternal Serum Aneuploidy Screen and Adverse Pregnancy Outcomes

2016 ◽  
Vol 66 (S1) ◽  
pp. 141-148 ◽  
Author(s):  
Koumudi Godbole ◽  
Aparna Kulkarni ◽  
Asawari Kanade ◽  
Shilpa Kulkarni ◽  
Girish Godbole ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Maternal Serum ◽  
Adverse Pregnancy Outcomes ◽  
Adverse Pregnancy

scholarly journals 390: Serum screening for aneuploidy generates an enriched population at risk for adverse pregnancy outcomes

2011 ◽  
Vol 204 (1) ◽  
pp. S159
Author(s):  
Kristen Quinn ◽  
Veronique Tache ◽  
Andrew Hull ◽  
Louise Laurent ◽  
Douglas Woelkers
Keyword(s):  
At Risk ◽  
Pregnancy Outcomes ◽  
Adverse Pregnancy Outcomes ◽  
Population At Risk ◽  
Serum Screening ◽  
Adverse Pregnancy

Prenatal Screening

2018 ◽  
Author(s):  
Amber Mathiesen ◽  
Kali Roy
Keyword(s):  
Test Performance ◽  
Predictive Value ◽  
Prenatal Screening ◽  
Maternal Serum ◽  
Dna Testing ◽  
Maternal Serum Screening ◽  
Cell Free Dna ◽  
Free Dna ◽  
Serum Screening

This chapter provides information about a genetic counselor’s role in prenatal screening, including discussing and offering options to a patient, interpreting and providing results, or managing referrals based on abnormal results. It discusses how a screen is evaluated using sensitivity, specificity, positive predictive value, negative predictive value, and personal utility. It provides a detailed description of both maternal serum screening and cell-free DNA testing. The maternal serum screening discussion includes information on multiples of median, calculating risk, timing, pattern association, limitations, and follow-up. The review of cell-free DNA testing includes fetal fraction, methodology, test performance, limitations and considerations for testing, and follow-up. This chapter also provides a list of additional resources to use for cell-free DNA testing.

scholarly journals Mid-Trimester Maternal Serum AFP and hCG as Markers of Preterm and Term Adverse Pregnancy Outcomes

2015 ◽  
Vol 37 (2) ◽  
pp. 111-116 ◽  
Author(s):  
Sabrina Tancrède ◽  
Emmanuel Bujold ◽  
Yves Giguère ◽  
Marie-Hélène Renald ◽  
Joel Girouard ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Maternal Serum ◽  
Adverse Pregnancy Outcomes ◽  
Adverse Pregnancy
Sign in / Sign up

Export Citation Format

Share Document